The DeLOS II trial is a multicenter randomised phase II trial investigating a
TP/5-Fluorouracil (TPF)-chemotherapy with or without cetuximab for Patients with only by
laryngectomy operable carcinoma of the larynx/hypopharynx. Patients were divided in responder
or non-responder after 4 weeks. Since August 2009 Responder receive TP with or without
Cetuximab + radiation. (Until february 2009 Responder received TPF with or without Cetuximab
+ radiation.) Planned accrual is 85 patients per treatment arm. The primary study endpoint is
a confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2
years after randomisation.